Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 99

1.

Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research.

Lazaryan A, Dolan M, Zhang MJ, Wang HL, Kharfan-Dabaja MA, Marks DI, Bejanyan N, Copelan E, Majhail NS, Waller EK, Chao N, Prestidge T, Nishihori T, Kebriaei P, Inamoto Y, Hamilton B, Hashmi SK, Kamble RT, Bacher U, Hildebrandt GC, Stiff PJ, McGuirk J, Aldoss I, Beitinjaneh AM, Muffly L, Vij R, Olsson RF, Byrne M, Schultz KR, Aljurf M, Seftel M, Savoie ML, Savani BN, Verdonck LF, Cairo MS, Hossain N, Bhatt VR, Frangoul HA, Abdel-Azim H, Al Malki M, Munker R, Rizzieri D, Khera N, Nakamura R, Ringdén O, van der Poel M, Murthy HS, Liu H, Mori S, De Oliveira S, Bolaños-Meade J, Elsawy M, Barba P, Nathan S, George B, Pawarode A, Grunwald M, Agrawal V, Wang Y, Assal A, Castillo Caro P, Kuwatsuka Y, Seo S, Ustun C, Politikos I, Lazarus HM, Saber W, Sandmaier BM, De Lima M, Litzow M, Bachanova V, Weisdorf D; Acute Leukemia Committee of the CIBMTR.

Haematologica. 2019 Sep 26. pii: haematol.2019.220756. doi: 10.3324/haematol.2019.220756. [Epub ahead of print]

2.

Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy.

DeFilipp Z, Advani AS, Bachanova V, Cassaday RD, Deangelo DJ, Kebriaei P, Rowe JM, Seftel MD, Stock W, Tallman MS, Fanning S, Inamoto Y, Kansagra A, Johnston L, Nagler A, Sauter CS, Savani BN, Perales MA, Carpenter PA, Larson RA, Weisdorf D.

Biol Blood Marrow Transplant. 2019 Nov;25(11):2113-2123. doi: 10.1016/j.bbmt.2019.08.014. Epub 2019 Aug 22. Review.

PMID:
31446198
3.

Inferior Access to Allogeneic Transplant in Disadvantaged Populations: A Center for International Blood and Marrow Transplant Research Analysis.

Paulson K, Brazauskas R, Khera N, He N, Majhail N, Akpek G, Aljurf M, Buchbinder D, Burns L, Beattie S, Freytes C, Garcia A, Gajewski J, Hahn T, Knight J, LeMaistre C, Lazarus H, Szwajcer D, Seftel M, Wirk B, Wood W, Saber W.

Biol Blood Marrow Transplant. 2019 Oct;25(10):2086-2090. doi: 10.1016/j.bbmt.2019.06.012. Epub 2019 Jun 19.

PMID:
31228584
4.

Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.

Grigor EJM, Fergusson D, Kekre N, Montroy J, Atkins H, Seftel MD, Daugaard M, Presseau J, Thavorn K, Hutton B, Holt RA, Lalu MM.

Transfus Med Rev. 2019 Apr;33(2):98-110. doi: 10.1016/j.tmrv.2019.01.005. Epub 2019 Feb 14. Review.

5.

Recognizing subclinical hyposplenism.

Seftel MD.

CMAJ. 2019 Jan 7;191(1):E21. doi: 10.1503/cmaj.70852. No abstract available.

6.

Fludarabine, busulfan, and low-dose TBI conditioning versus cyclophosphamide and TBI in allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia.

Speziali C, Daly A, Abuhaleeqa M, Nitta J, Abou Mourad Y, Seftel MD, Paulson K.

Leuk Lymphoma. 2019 Mar;60(3):639-648. doi: 10.1080/10428194.2018.1493734. Epub 2018 Aug 30.

PMID:
30160568
7.

Bilateral adrenal hemorrhage as a manifestation of extramedullary hematopoiesis in a patient with primary myelofibrosis.

Uminski K, Kumar R, Seftel M.

Ann Hematol. 2018 Oct;97(10):2011-2012. doi: 10.1007/s00277-018-3352-3. Epub 2018 May 1. No abstract available.

PMID:
29713748
8.

Country-Level Macroeconomic Indicators Predict Early Post-Allogeneic Hematopoietic Cell Transplantation Survival in Acute Lymphoblastic Leukemia: A CIBMTR Analysis.

Wood WA, Brazauskas R, Hu ZH, Abdel-Azim H, Ahmed IA, Aljurf M, Badawy S, Beitinjaneh A, George B, Buchbinder D, Cerny J, Dedeken L, Diaz MA, Freytes CO, Ganguly S, Gergis U, Almaguer DG, Gupta A, Hale G, Hashmi SK, Inamoto Y, Kamble RT, Adekola K, Kindwall-Keller T, Knight J, Kumar L, Kuwatsuka Y, Law J, Lazarus HM, LeMaistre C, Olsson RF, Pulsipher MA, Savani BN, Schultz KR, Saad AA, Seftel M, Seo S, Shea TC, Steinberg A, Sullivan K, Szwajcer D, Wirk B, Yared J, Yong A, Dalal J, Hahn T, Khera N, Bonfim C, Atsuta Y, Saber W.

Biol Blood Marrow Transplant. 2018 Sep;24(9):1928-1935. doi: 10.1016/j.bbmt.2018.03.016. Epub 2018 Mar 19.

9.

Choosing Wisely BMT: American Society for Blood and Marrow Transplantation and Canadian Blood and Marrow Transplant Group's List of 5 Tests and Treatments to Question in Blood and Marrow Transplantation.

Bhella S, Majhail NS, Betcher J, Costa LJ, Daly A, Dandoy CE, DeFilipp Z, Doan V, Gulbis A, Hicks L, Juckett M, Khera N, Krishnan A, Selby G, Shah NN, Stricherz M, Viswabandya A, Bredeson C, Seftel MD.

Biol Blood Marrow Transplant. 2018 May;24(5):909-913. doi: 10.1016/j.bbmt.2018.01.017. Epub 2018 Jan 31. Review.

10.

Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in patients with haematological and solid malignancies: protocol for a systematic review and meta-analysis.

Grigor EJM, Fergusson DA, Haggar F, Kekre N, Atkins H, Shorr R, Holt RA, Hutton B, Ramsay T, Seftel M, Jonker D, Daugaard M, Thavorn K, Presseau J, Lalu MM.

BMJ Open. 2017 Dec 29;7(12):e019321. doi: 10.1136/bmjopen-2017-019321.

11.

Pretransplant Consolidation Is Not Beneficial for Adults with ALL Undergoing Myeloablative Allogeneic Transplantation.

Bejanyan N, Zhang MJ, Wang HL, Lazaryan A, de Lima M, Marks DI, Sandmaier BM, Bachanova V, Rowe J, Tallman M, Kebriaei P, Kharfan-Dabaja M, Peter Gale R, Lazarus HM, Ustun C, Copelan E, Ky Hamilton B, Schiller G, Hogan W, Hashmi S, Seftel M, Kanakry CG, Olsson RF, Martino R, Saber W, Khoury HJ, Weisdorf DJ.

Biol Blood Marrow Transplant. 2018 May;24(5):945-955. doi: 10.1016/j.bbmt.2017.12.784. Epub 2017 Dec 21.

12.

The use of prophylactic anticoagulation during induction and consolidation chemotherapy in adults with acute lymphoblastic leukemia.

Grace RF, DeAngelo DJ, Stevenson KE, Neuberg D, Sallan SE, Mourad YRA, Bergeron J, Seftel MD, Kokulis C, Connors JM.

J Thromb Thrombolysis. 2018 Feb;45(2):306-314. doi: 10.1007/s11239-017-1597-7.

PMID:
29260426
13.

Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia.

Kebriaei P, Anasetti C, Zhang MJ, Wang HL, Aldoss I, de Lima M, Khoury HJ, Sandmaier BM, Horowitz MM, Artz A, Bejanyan N, Ciurea S, Lazarus HM, Gale RP, Litzow M, Bredeson C, Seftel MD, Pulsipher MA, Boelens JJ, Alvarnas J, Champlin R, Forman S, Pullarkat V, Weisdorf D, Marks DI; Acute Leukemia Committee of the CIBMTR.

Biol Blood Marrow Transplant. 2018 Apr;24(4):726-733. doi: 10.1016/j.bbmt.2017.11.025. Epub 2017 Dec 25.

14.

Assessment of Impact of HLA Type on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia.

Hill BT, Ahn KW, Hu ZH, Aljurf M, Beitinjaneh A, Cahn JY, Cerny J, Kharfan-Dabaja MA, Ganguly S, Ghosh N, Grunwald MR, Inamoto Y, Kindwall-Keller T, Nishihori T, Olsson RF, Saad A, Seftel M, Seo S, Szer J, Tallman M, Ustun C, Wiernik PH, Maziarz RT, Kalaycio M, Alyea E, Popat U, Sobecks R, Saber W.

Biol Blood Marrow Transplant. 2018 Mar;24(3):581-586. doi: 10.1016/j.bbmt.2017.10.015. Epub 2017 Oct 12.

15.

Donor Experiences of Second Marrow or Peripheral Blood Stem Cell Collection Mirror the First, but CD34+ Yields Are Less.

Stroncek DF, Shaw BE, Logan BR, Kiefer DM, Savani BN, Anderlini P, Bredeson CN, Hematti P, Ganguly S, Diaz MA, Abdel-Azim H, Ahmed I, Maharaj D, Seftel M, Beitinjaneh A, Seo S, Yared JA, Halter J, O'Donnell PV, Hale GA, DeFilipp Z, Lazarus H, Liesveld JL, Zhou Z, Munshi P, Olsson RF, Kasow KA, Szer J, Switzer GE, Chitphakdithai P, Shah N, Confer DL, Pulsipher MA.

Biol Blood Marrow Transplant. 2018 Jan;24(1):175-184. doi: 10.1016/j.bbmt.2017.09.013. Epub 2017 Sep 25.

16.

Economic evaluation of rituximab in addition to standard of care chemotherapy for adult patients with acute lymphoblastic leukemia.

Nam J, Milenkovski R, Yunger S, Geirnaert M, Paulson K, Seftel M.

J Med Econ. 2018 Jan;21(1):47-59. doi: 10.1080/13696998.2017.1372230. Epub 2017 Sep 18.

PMID:
28837377
17.

Burkitt's Lymphoma and B-Cell Lymphoma Unclassifiable With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt's Lymphoma in Patients With HIV: Outcomes in a South African Public Hospital.

Sissolak G, Seftel M, Uldrick TS, Esterhuizen TM, Mohamed N, Kotze D.

J Glob Oncol. 2016 Aug 31;3(3):218-226. doi: 10.1200/JGO.2015.002378. eCollection 2017 Jun.

18.

Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States.

Muffly L, Pasquini MC, Martens M, Brazauskas R, Zhu X, Adekola K, Aljurf M, Ballen KK, Bajel A, Baron F, Battiwalla M, Beitinjaneh A, Cahn JY, Carabasi M, Chen YB, Chhabra S, Ciurea S, Copelan E, D'Souza A, Edwards J, Foran J, Freytes CO, Fung HC, Gale RP, Giralt S, Hashmi SK, Hildebrandt GC, Ho V, Jakubowski A, Lazarus H, Luskin MR, Martino R, Maziarz R, McCarthy P, Nishihori T, Olin R, Olsson RF, Pawarode A, Peres E, Rezvani AR, Rizzieri D, Savani BN, Schouten HC, Sabloff M, Seftel M, Seo S, Sorror ML, Szer J, Wirk BM, Wood WA, Artz A.

Blood. 2017 Aug 31;130(9):1156-1164. doi: 10.1182/blood-2017-03-772368. Epub 2017 Jul 3.

19.

Improved prognostic stratification power of CIBMTR risk score with the addition of absolute lymphocyte and eosinophil counts at the onset of chronic GVHD.

Moon JH, Hamad N, Sohn SK, Uhm J, Alam N, Gupta V, Lipton JH, Messner HA, Seftel M, Kuruvilla J, Kim DD.

Ann Hematol. 2017 May;96(5):805-815. doi: 10.1007/s00277-017-2939-4. Epub 2017 Feb 18.

PMID:
28214979
20.

Myeloablative versus Reduced-Intensity Conditioning in Patients with Myeloid Malignancies: A Propensity Score-Matched Analysis.

Sibai H, Falcone U, Deotare U, Michelis FV, Uhm J, Gupta V, Kuruvilla J, Lipton JH, Seftel MD, Messner HA, Kim DDH.

Biol Blood Marrow Transplant. 2016 Dec;22(12):2270-2275. doi: 10.1016/j.bbmt.2016.08.030. Epub 2016 Sep 3.

21.

The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group.

Seftel MD, Kuruvilla J, Kouroukis T, Banerji V, Fraser G, Crump M, Kumar R, Chalchal HI, Salim M, Laister RC, Crocker S, Gibson SB, Toguchi M, Lyons JF, Xu H, Powers J, Sederias J, Seymour L, Hay AE.

Leuk Lymphoma. 2017 Jun;58(6):1358-1365. doi: 10.1080/10428194.2016.1239259. Epub 2016 Oct 17.

PMID:
27750483
22.

Reduced intensity conditioned allograft yields favorable survival for older adults with B-cell acute lymphoblastic leukemia.

Rosko A, Wang HL, de Lima M, Sandmaier B, Khoury HJ, Artz A, Brammer J, Bredeson C, Farag S, Kharfan-Dabaja M, Lazarus HM, Marks DI, Bufarull RM, McGuirk J, Mohty M, Nishihori T, Nivison-Smith I, Rashidi A, Ringden O, Seftel M, Weisdorf D, Bachanova V, Saber W.

Am J Hematol. 2017 Jan;92(1):42-49. doi: 10.1002/ajh.24575. Epub 2016 Nov 12.

23.

A pharmacogenetic analysis of the Canadian Cancer Trials Group MY.10 clinical trial of maintenance therapy for multiple myeloma.

Han M, Murugesan A, Bahlis NJ, Song K, White D, Chen C, Seftel MD, Howsen-Jan K, Reece D, Stewart K, Xie Y, Hay AE, Shepherd L, Djurfeldt M, Zhu L, Meyer RM, Chen BE, Reiman T.

Blood. 2016 Aug 4;128(5):732-5. doi: 10.1182/blood-2016-06-716902. Epub 2016 Jun 23. No abstract available.

PMID:
27338095
24.

Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial.

Carde P, Karrasch M, Fortpied C, Brice P, Khaled H, Casasnovas O, Caillot D, Gaillard I, Bologna S, Ferme C, Lugtenburg PJ, Morschhauser F, Aurer I, Coiffier B, Meyer R, Seftel M, Wolf M, Glimelius B, Sureda A, Mounier N.

J Clin Oncol. 2016 Jun 10;34(17):2028-36. doi: 10.1200/JCO.2015.64.5648. Epub 2016 Apr 25.

PMID:
27114593
25.

Impact of early CMV reactivation in cord blood stem cell recipients in the current era.

Ramanathan M, Teira P, Battiwalla M, Barrett J, Ahn KW, Chen M, Green J, Laughlin M, Lazarus HM, Marks D, Saad A, Seftel M, Saber W, Savani B, Waller EK, Wingard J, Auletta JJ, Lindemans CA, Boeckh M, Riches ML.

Bone Marrow Transplant. 2016 Aug;51(8):1113-20. doi: 10.1038/bmt.2016.89. Epub 2016 Apr 4.

26.

Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia in Adults.

Speziali C, Paulson K, Seftel M.

Curr Hematol Malig Rep. 2016 Jun;11(3):175-84. doi: 10.1007/s11899-016-0317-2. Review.

PMID:
26984203
27.

Extracorporeal photopheresis in solid organ transplant-associated acute graft-versus-host disease.

Houston BL, Yan M, Tinckam K, Kamel-Reid S, Chang H, Kuo KH, Tsien C, Seftel MD, Avitzur Y, Grant D, Cserti-Gazdewich CM.

Transfusion. 2016 Apr;56(4):962-9. doi: 10.1111/trf.13467. Epub 2016 Feb 18.

PMID:
26892365
28.

Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis.

Teira P, Battiwalla M, Ramanathan M, Barrett AJ, Ahn KW, Chen M, Green JS, Saad A, Antin JH, Savani BN, Lazarus HM, Seftel M, Saber W, Marks D, Aljurf M, Norkin M, Wingard JR, Lindemans CA, Boeckh M, Riches ML, Auletta JJ.

Blood. 2016 May 19;127(20):2427-38. doi: 10.1182/blood-2015-11-679639. Epub 2016 Feb 16.

29.

Comparing Outcomes with Bone Marrow or Peripheral Blood Stem Cells as Graft Source for Matched Sibling Transplants in Severe Aplastic Anemia across Different Economic Regions.

Kumar R, Kimura F, Ahn KW, Hu ZH, Kuwatsuka Y, Klein JP, Pasquini M, Miyamura K, Kato K, Yoshimi A, Inamoto Y, Ichinohe T, Wood WA Jr, Wirk B, Seftel M, Rowlings P, Marks DI, Schultz KR, Gupta V, Dedeken L, George B, Cahn JY, Szer J, Lee JW, Ho AY, Fasth A, Hahn T, Khera N, Dalal J, Bonfim C, Aljurf M, Atsuta Y, Saber W.

Biol Blood Marrow Transplant. 2016 May;22(5):932-40. doi: 10.1016/j.bbmt.2016.01.012. Epub 2016 Jan 18.

30.

A phase I study of elesclomol sodium in patients with acute myeloid leukemia.

Hedley D, Shamas-Din A, Chow S, Sanfelice D, Schuh AC, Brandwein JM, Seftel MD, Gupta V, Yee KW, Schimmer AD.

Leuk Lymphoma. 2016 Oct;57(10):2437-40. doi: 10.3109/10428194.2016.1138293. Epub 2016 Feb 5. No abstract available.

PMID:
26732437
31.

The incidence, mortality and timing of Pneumocystis jiroveci pneumonia after hematopoietic cell transplantation: a CIBMTR analysis.

Williams KM, Ahn KW, Chen M, Aljurf MD, Agwu AL, Chen AR, Walsh TJ, Szabolcs P, Boeckh MJ, Auletta JJ, Lindemans CA, Zanis-Neto J, Malvezzi M, Lister J, de Toledo Codina JS, Sackey K, Chakrabarty JL, Ljungman P, Wingard JR, Seftel MD, Seo S, Hale GA, Wirk B, Smith MS, Savani BN, Lazarus HM, Marks DI, Ustun C, Abdel-Azim H, Dvorak CC, Szer J, Storek J, Yong A, Riches MR.

Bone Marrow Transplant. 2016 Apr;51(4):573-80. doi: 10.1038/bmt.2015.316. Epub 2016 Jan 4.

32.

Pediatric-inspired therapy compared to allografting for Philadelphia chromosome-negative adult ALL in first complete remission.

Seftel MD, Neuberg D, Zhang MJ, Wang HL, Ballen KK, Bergeron J, Couban S, Freytes CO, Hamadani M, Kharfan-Dabaja MA, Lazarus HM, Nishihori T, Paulson K, Saber W, Sallan SE, Soiffer R, Tallman MS, Woolfrey AE, DeAngelo DJ, Weisdorf DJ; Acute Leukemia Committee of the CIBMTR and the Dana Farber ALL Consortium.

Am J Hematol. 2016 Mar;91(3):322-9. doi: 10.1002/ajh.24285.

33.

Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: 10-Color flow cytometry diagnosis and HyperCVAD therapy.

Deotare U, Yee KW, Le LW, Porwit A, Tierens A, Musani R, Barth D, Torlakovic E, Schimmer A, Schuh AC, Seftel M, Minden MD, Gupta V, Hyjek E.

Am J Hematol. 2016 Mar;91(3):283-6. doi: 10.1002/ajh.24258. Epub 2016 Jan 11.

34.

Significant Improvements in the Practice Patterns of Adult Related Donor Care in US Transplantation Centers.

Anthias C, Shaw BE, Kiefer DM, Liesveld JL, Yared J, Kamble RT, D'Souza A, Hematti P, Seftel MD, Norkin M, DeFilipp Z, Kasow KA, Abidi MH, Savani BN, Shah NN, Anderlini P, Diaz MA, Malone AK, Halter JP, Lazarus HM, Logan BR, Switzer GE, Pulsipher MA, Confer DL, O'Donnell PV.

Biol Blood Marrow Transplant. 2016 Mar;22(3):520-7. doi: 10.1016/j.bbmt.2015.11.008. Epub 2015 Nov 18.

35.

Hematopoietic Cell Transplantation as Curative Therapy for Patients with Myelofibrosis: Long-Term Success in all Age Groups.

Deeg HJ, Bredeson C, Farnia S, Ballen K, Gupta V, Mesa RA, Popat U, Hari P, Saber W, Seftel M, Tamari R, Petersdorf EW.

Biol Blood Marrow Transplant. 2015 Nov;21(11):1883-7. doi: 10.1016/j.bbmt.2015.09.005. Epub 2015 Sep 11. Review.

36.

Patient age, remission status and HCT-CI in a combined score are prognostic for patients with AML undergoing allogeneic hematopoietic cell transplantation in CR1 and CR2.

Michelis FV, Messner HA, Atenafu EG, McGillis L, Lambie A, Uhm J, Alam N, Seftel MD, Gupta V, Kuruvilla J, Lipton JH, Kim DD.

Bone Marrow Transplant. 2015 Nov;50(11):1405-10. doi: 10.1038/bmt.2015.165. Epub 2015 Jul 13.

PMID:
26168067
37.

Outcomes of patients with therapy-related AML/myelodysplastic syndrome (t-AML/MDS) following hematopoietic cell transplantation.

Alam N, Atenafu EG, Kuruvilla J, Uhm J, Lipton JH, Messner HA, Kim DH, Seftel M, Gupta V.

Bone Marrow Transplant. 2015 Sep;50(9):1180-6. doi: 10.1038/bmt.2015.151. Epub 2015 Jun 29.

PMID:
26121109
38.

Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12.

Kuruvilla J, MacDonald DA, Kouroukis CT, Cheung M, Olney HJ, Turner AR, Anglin P, Seftel M, Ismail WS, Luminari S, Couban S, Baetz T, Meyer RM, Hay AE, Shepherd L, Djurfeldt MS, Alamoudi S, Chen BE, Crump M.

Blood. 2015 Aug 6;126(6):733-8. doi: 10.1182/blood-2015-01-622084. Epub 2015 Jun 24.

PMID:
26109202
39.

Impaired T cell responsiveness to interleukin-6 in hematological patients with invasive aspergillosis.

Camargo JF, Bhimji A, Kumar D, Kaul R, Pavan R, Schuh A, Seftel M, Lipton JH, Gupta V, Humar A, Husain S.

PLoS One. 2015 Apr 2;10(4):e0123171. doi: 10.1371/journal.pone.0123171. eCollection 2015.

40.

Comparable outcomes post allogeneic hematopoietic cell transplant for patients with de novo or secondary acute myeloid leukemia in first remission.

Michelis FV, Atenafu EG, Gupta V, Kim DD, Kuruvilla J, Lipton JH, Loach D, Seftel MD, Uhm J, Alam N, Lambie A, McGillis L, Messner HA.

Bone Marrow Transplant. 2015 Jul;50(7):907-13. doi: 10.1038/bmt.2015.59. Epub 2015 Mar 30.

PMID:
25822226
41.

Risk model incorporating donor IL6 and IFNG genotype and gastrointestinal GVHD can discriminate patients at high risk of steroid refractory acute GVHD.

Alam N, Xu W, Atenafu EG, Uhm J, Seftel M, Gupta V, Kuruvilla J, Lipton JH, Messner HA, Kim DD.

Bone Marrow Transplant. 2015 May;50(5):734-42. doi: 10.1038/bmt.2015.19. Epub 2015 Mar 16.

PMID:
25774595
42.

Mycophenolate-based graft versus host disease prophylaxis is not inferior to methotrexate in myeloablative-related donor stem cell transplantation.

Hamad N, Shanavas M, Michelis FV, Uhm J, Gupta V, Seftel M, Kuruvilla J, Lipton JH, Messner HA, Kim DD.

Am J Hematol. 2015 May;90(5):392-9. doi: 10.1002/ajh.23955. Epub 2015 Apr 8.

43.

Modified EBMT Pretransplant Risk Score Can Identify Favorable-risk Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for AML, Not Identified by the HCT-CI Score.

Michelis FV, Messner HA, Uhm J, Alam N, Lambie A, McGillis L, Seftel MD, Gupta V, Kuruvilla J, Lipton JH, Kim DD.

Clin Lymphoma Myeloma Leuk. 2015 May;15(5):e73-81. doi: 10.1016/j.clml.2014.09.014. Epub 2014 Oct 5.

PMID:
25458081
44.

A Canadian consensus on the management of newly diagnosed and relapsed acute promyelocytic leukemia in adults.

Seftel MD, Barnett MJ, Couban S, Leber B, Storring J, Assaily W, Fuerth B, Christofides A, Schuh AC.

Curr Oncol. 2014 Oct;21(5):234-50. doi: 10.3747/co.21.2183.

45.

The risk of polyomavirus BK-associated hemorrhagic cystitis after allogeneic hematopoietic SCT is associated with myeloablative conditioning, CMV viremia and severe acute GVHD.

Uhm J, Hamad N, Michelis FV, Shanavas M, Kuruvilla J, Gupta V, Lipton JH, Messner HA, Seftel M, Kim DD.

Bone Marrow Transplant. 2014 Dec;49(12):1528-34. doi: 10.1038/bmt.2014.181. Epub 2014 Aug 11.

PMID:
25111517
46.

Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia.

DeAngelo DJ, Stevenson KE, Dahlberg SE, Silverman LB, Couban S, Supko JG, Amrein PC, Ballen KK, Seftel MD, Turner AR, Leber B, Howson-Jan K, Kelly K, Cohen S, Matthews JH, Savoie L, Wadleigh M, Sirulnik LA, Galinsky I, Neuberg DS, Sallan SE, Stone RM.

Leukemia. 2015 Mar;29(3):526-34. doi: 10.1038/leu.2014.229. Epub 2014 Jul 31.

47.

Incidence, risk factors, and long-term outcomes of sclerotic graft-versus-host disease after allogeneic hematopoietic cell transplantation.

Uhm J, Hamad N, Shin EM, Michelis FV, Shanavas M, Gupta V, Kuruvilla J, Lipton JH, Messner HA, Seftel M, Kim DD.

Biol Blood Marrow Transplant. 2014 Nov;20(11):1751-7. doi: 10.1016/j.bbmt.2014.07.001. Epub 2014 Jul 17.

48.

Outcomes of hematopoietic cell transplantation in adult patients with acquired aplastic anemia using intermediate-dose alemtuzumab-based conditioning.

Hamad N, Del Bel R, Messner HA, Kim D, Kuruvilla J, Lipton JH, Uhm J, Seftel M, Alam N, Xu W, Gupta V.

Biol Blood Marrow Transplant. 2014 Nov;20(11):1722-8. doi: 10.1016/j.bbmt.2014.06.033. Epub 2014 Jul 10.

49.

Allogeneic hematopoietic cell transplantation for myelofibrosis using fludarabine-, intravenous busulfan- and low-dose TBI-based conditioning.

Shanavas M, Messner HA, Atenafu EG, Kim DH, Kuruvilla J, Lipton JH, Uhm J, Seftel M, Alam N, Gupta V.

Bone Marrow Transplant. 2014 Sep;49(9):1162-9. doi: 10.1038/bmt.2014.131. Epub 2014 Jun 30.

PMID:
24978138
50.

Outcomes of human leukocyte antigen-matched sibling donor hematopoietic cell transplantation in chronic lymphocytic leukemia: myeloablative versus reduced-intensity conditioning regimens.

Sobecks RM, Leis JF, Gale RP, Ahn KW, Zhu X, Sabloff M, de Lima M, Brown JR, Inamoto Y, Hale GA, Aljurf MD, Kamble RT, Hsu JW, Pavletic SZ, Wirk B, Seftel MD, Lewis ID, Alyea EP, Cortes J, Kalaycio ME, Maziarz RT, Saber W.

Biol Blood Marrow Transplant. 2014 Sep;20(9):1390-8. doi: 10.1016/j.bbmt.2014.05.020. Epub 2014 May 28.

Supplemental Content

Loading ...
Support Center